Skip to content
value.today

Biotime Inc.

Total raised
$20 M
3 rounds on record
Latest round
$8 M
May 2010
First round on record
Apr 2009
Today
Went public
See the company page

Biotime Inc. is listed today as Lineage Cell Therapeutics, Inc.: market value, financials and filings are on its company page.

Funding rounds

3 counted as startup funding, 3 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Biotime Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Mar 2014$4 MPrivate placement after listing$2 to $10 million

Biotime Inc.: Private sale, Mar 2014

Investors in this round

3 investors had bought by the notice of Mar 7, 2014: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $15 M offered; $12 M still to sell
Smallest investment taken
$500,000
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
$1 million to $5 million
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in California

People named in the notice

  • Michael D West · Executive Officer, Director
  • Robert W Peabody · Executive Officer
  • William P. Tew · Executive Officer
  • Alfred D Kingsley · Director
  • Andrew C. von Eschenbach · Director
  • Franklin M. Berger · Director
  • Henry L. Nordhoff · Director
  • Judith D Segall · Director
  • Neal C Bradsher · Director
  • Pedro D Lichtinger · Director
  • Stephen C. Farrell · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Judith Segall, Corporate Secretary. Source: SEC Form D, newest notice filed Mar 7, 2014. Read the notice at the SEC.

equity, optionsSEC
Mar 2011$4 MIssued in a merger or acquisition$2 to $10 million

Biotime Inc.: Private sale, Mar 2011

Investors in this round

20 investors had bought by the notice of Mar 24, 2011: 19 accredited, 1 not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $4 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
$1 million to $5 million
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in California

People named in the notice

  • Judith D Segall · Executive Officer, Director
  • Michael D West · Executive Officer, Director
  • Robert W Peabody · Executive Officer
  • Walter W Funk · Executive Officer
  • Abraham E Cohen · Director
  • Alfred D Kingsley · Director
  • Arnold I Burns · Director
  • Neal C Bradsher · Director
  • Pedro D Lichtinger · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Shares and warrants issued in merger”

Signed by Judith Segall, Corporate Secretary. Source: SEC Form D, newest notice filed Mar 24, 2011. Read the notice at the SEC.

equity, optionsSEC
Jan 2011$2 MIssued in a merger or acquisition$2 to $10 million

Biotime Inc.: Private sale, Jan 2011

Investors in this round

8 investors had bought by the notice of Feb 2, 2011: 6 accredited, 2 not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 505: the former limited-offering exemption (withdrawn in 2017)
  • 06
Meant to last
a year or less
Issuer's revenue
$1 million to $5 million
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in California

People named in the notice

  • Judith D Segall · Executive Officer, Director
  • Michael D West · Executive Officer, Director
  • Robert W Peabody · Executive Officer
  • Walter W Funk · Executive Officer
  • Abraham E Cohen · Director
  • Alfred D Kingsley · Director
  • Arnold I Burns · Director
  • Neal C Bradsher · Director
  • Pedro D Lichtinger · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Shares issued in exchange for assets”

Signed by Judith Segall, Corporate Secretary. Source: SEC Form D, newest notice filed Feb 2, 2011. Read the notice at the SEC.

equitySEC
May 2010$8 MNo. 3$2 to $10 million

Biotime Inc.: Raise no. 3, May 2010

Investors in this round

2 investors had bought by the notice of May 21, 2010: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$8 M of $8 M offered
Smallest investment taken
$4,000,000
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
$1 million to $5 million
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in California

People named in the notice

  • Michael D West · Executive Officer, Director
  • Robert W Peabody · Executive Officer
  • Steven A Seinberg · Executive Officer
  • Walter W Funk · Executive Officer
  • Abraham E Cohen · Director
  • Alfred D Kingsley · Director
  • Arnold I Burns · Director
  • Judith D Segall · Director
  • Neal C Bradsher · Director
  • Pedro D Lichtinger · Director
  • Robert N Butler · Director
  • Valeta A Gregg · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “4,400,000 shares at $1.818 per share”

Signed by Robert Peabody, Chief Operating Officer. Source: SEC Form D, newest notice filed May 21, 2010. Read the notice at the SEC.

equitySEC
May 2009$8 MNo. 2$2 to $10 million

Biotime Inc.: Raise no. 2, May 2009

Investors in this round

2 investors had bought by the notice of Jul 14, 2009: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$8 M of $17 M offered; $9 M still to sell
Smallest investment taken
$2,000,000
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
$1 million to $5 million
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in California

People named in the notice

  • Hal Sternberg · Executive Officer, Director
  • Harold Waitz · Executive Officer, Director
  • Judith Segall · Executive Officer, Director
  • Michael D West · Executive Officer, Director
  • Robert W Peabody · Executive Officer
  • Steven A Seinberg · Executive Officer
  • Abraham E Cohen · Director
  • Alfred D Kingsley · Director
  • Arnold I Burns · Director
  • Neal C Bradsher · Director
  • Robert N Butler · Director
  • Valeta Gregg · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Remaining amount issuable upon exercise of warrants.”

Signed by Steven A Seinberg, Chief Financial Officer. Source: SEC Form D and 1 amendment, newest notice filed Jul 14, 2009. Read the notice at the SEC.

equity, optionsSEC
Apr 2009$4 MNo. 1$2 to $10 million

Biotime Inc.: Raise no. 1, Apr 2009

Investors in this round

29 investors had bought by the notice of May 21, 2009: 29 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M (amount offered: indefinite)
Smallest investment taken
no minimum stated
What was sold
equity, debt
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
$1 million to $5 million
Sales commissions
$23,000
Finders' fees
$5,000
Paid to its own people
$625,000 (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions and finders' fees and payments to its own people as estimates
The company
Corporation, incorporated in Ca

People named in the notice

  • Hal Sternberg · Executive Officer, Director
  • Harold Waitz · Executive Officer, Director
  • Judith Segall · Executive Officer, Director
  • Michael D West · Executive Officer, Director
  • Robert W Peabody · Executive Officer
  • Steven A Seinberg · Executive Officer
  • Gregg Valeta · Director
  • Robert N Butler · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • unknown · broker-dealer Equity Source Partners (CRD 140227) · Jericho, NySold in no state named
  • Robert Kingsley · Chicago, IlSold in no state named

Remarks in the notice

  • On fees: “Plus warrants to purchase common stock”
  • On the amounts: “Revolving Line of Credit”
  • On the use of proceeds: “Salary payments”

Signed by Steven A Seinberg, Chief Financial Officer. Source: SEC Form D and 1 amendment, newest notice filed May 21, 2009. Read the notice at the SEC.

equity, debtSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • As the listed company Lineage Cell Therapeutics, Inc., its revenue in fiscal 2025 came from these product and service lines: Collaboration Revenues $13.61 million (93%), Event Based Milestones and Other Collaborative Revenue $7.16 million (49%), Upfront license fees $6.44 million (44%), Royalties, License and Other Revenues $950,000 (7%).

    Annual report (SEC XBRL) · Dec 2025

  • Biotime Inc. had revenue between $1 million and $5 million when it filed its newest notice of a funding round (Mar 2014).

    SEC Form D (revenue range) · Mar 2014

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Mar 2014

Products and services#

No products or services of Biotime Inc. are on record.

Investors#

No investor of Biotime Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 29 investors.

Largest shareholders today

Institutions holding Lineage Cell Therapeutics, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Biotime Inc.
NameRoleNamed in
Michael D WestExecutive officerMar 2014
Robert W PeabodyExecutive officerMar 2014
William P. TewExecutive officerMar 2014
Judith D SegallExecutive officerMar 2011
Walter W FunkExecutive officerMar 2011
Steven A SeinbergExecutive officerMay 2010
Hal SternbergExecutive officerJul 2009
Harold WaitzExecutive officerJul 2009
Judith SegallExecutive officerJul 2009
Alfred D KingsleyDirectorMar 2014
Andrew C. von EschenbachDirectorMar 2014
Franklin M. BergerDirectorMar 2014
Henry L. NordhoffDirectorMar 2014
Judith D SegallDirectorMar 2014
Michael D WestDirectorMar 2014
Neal C BradsherDirectorMar 2014
Pedro D LichtingerDirectorMar 2014
Stephen C. FarrellDirectorMar 2014
Abraham E CohenDirectorMar 2011
Arnold I BurnsDirectorMar 2011
Robert N ButlerDirectorMay 2010
Valeta A GreggDirectorMay 2010
Hal SternbergDirectorJul 2009
Harold WaitzDirectorJul 2009
Judith SegallDirectorJul 2009
Valeta GreggDirectorJul 2009
Gregg ValetaDirectorMay 2009

About

Company.

Went public since 2011. Its SEC number is that of a company listed on a stock exchange.